BofA Securities resumed coverage on Gilead Sciences with a new price target

12/10/24 8:28:11 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

BofA Securities resumed coverage of Gilead Sciences with a rating of Buy and set a new price target of $109.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GILD

Date	Price Target	Rating	Analyst
2/18/2025	$120.00	Hold → Buy	Deutsche Bank
2/13/2025	$108.00	Hold → Buy	DZ Bank
1/10/2025	$87.00 → $113.00	Equal-Weight → Overweight	Morgan Stanley
12/10/2024	$109.00	Buy	BofA Securities
11/15/2024	$110.00	Outperform	Wolfe Research
11/14/2024	$125.00	Buy	Citigroup
11/8/2024		Buy → Hold	Maxim Group
10/21/2024	$74.00 → $96.00	Market Perform → Outperform	Leerink Partners